No Data
Shanxi c&y pharmaceutical group (300254.SZ) subsidiary has received the pharmaceutical registration certificate and the approval notice for the application to market chemical raw materials.
Shanxi C&Y Pharmaceutical Group (300254.SZ) announced that recently, its subsidiary Hangzhou Qianyuan Baoling Pharmaceutical Co., Ltd. received...
Shanxi c&y pharmaceutical group (300254.SZ) plans to establish a wholly-owned subsidiary to accelerate the research and development of new products in categories such as refined and controlled drugs.
Shanxi c&y pharmaceutical group (300254.SZ) announced that on November 25, 2024, the company's fifth board of directors will hold its twenty...
shanxi c&y pharmaceutical group (300254.SZ): Subsidiary receives corporate support funds of 5 million yuan
Gelonghui, November 19th: Shanxi C&Y Pharmaceutical Group (300254.SZ) announced that its subsidiary, Tibet Shanxi C&Y Pharmaceutical Co., Ltd. (hereinafter referred to as "Tibet Shanxi C&Y"), received enterprise support funds of 5 million yuan from the Management Committee of Tibet Autonomous Region Tsangqing Industrial Park on November 19, 2024, accounting for 19.84% of the company's most recent audited net income.
shanxi c&y pharmaceutical group (300254.SZ): Currently, the company's products have not yet involved biotechnology.
Gelonghui November 11th | shanxi c&y pharmaceutical group (300254.SZ) stated on the investor interaction platform that currently the company's products are not yet involved in biotechnology synthesis technology.
There May Be Underlying Issues With The Quality Of ShanXi C&Y Pharmaceutical GroupLTD's (SZSE:300254) Earnings
Qianyuan Pharmaceutical: Report for the third quarter of 2024
ShanXi C&Y Pharmaceutical Group Co., Ltd. (SZSE:300254) Looks Inexpensive After Falling 28% But Perhaps Not Attractive Enough
